Influenza virus trivalent vaccine - GlaxoSmithKline

Drug Profile

Influenza virus trivalent vaccine - GlaxoSmithKline

Alternative Names: alpha-Rix; Fluarix; Fluarix Trivalent; Fluarix-VB; Inactivated influenza vaccine - GlaxoSmithKline; Influsplit SSW

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 01 Jul 2013 GlaxoSmithKline plans a phase III trial for Influenza virus infections (prevention) in Germany (NCT01884519)
  • 18 Jul 2011 US FDA approves Fluarix® for the 2011-2012 influenza season in USA
  • 31 Jul 2010 US FDA approves Fluarix® for the 2010-2011 influenza season in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top